Verastem Oncology has announced a significant milestone with the recent FDA approval of the combination therapy avutometinib plus defactinib for treating KRAS-mutated recurrent low-grade serous ovarian cancer. This approval is grounded in the promising results from the FRAME study, which demonstrated significant clinical activity and safety of this combination. The study showed a noteworthy objective response rate and progression-free survival, particularly in patients with KRAS mutations. This approval supports Verastem's commitment to advancing treatments for RAS/MAPK pathway-driven cancers, and the therapy is now being tested in other solid tumors, including in a global Phase 3 trial for first-line metastatic pancreatic cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.